# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-25-000069
**Filing Date:** 2025-10
**Character Count:** 14577
**Document Hash:** 940539b404feef7baf89798112dc49b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-25-000069.hdr.sgml**: 20251002

**ACCESSION NUMBER**: 0001648257-25-000069

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251002

**FILED AS OF DATE**: 20251002

**DATE AS OF CHANGE**: 20251002

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 251366996

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the Month of October 2025**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| Exhibit 99.1 |  | Press release relating to clinical data to be presented at the ESMO Congress 2025 |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: October 2, 2025

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20251002xex99d1001.gif)

**Press Release**

#### HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
**Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 2, 2025:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany.

Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions.

Details of the presentations are as follows:

---

| | | |
|:---|:---|:---|
| <br>**Abstract title**<br><BORDER_TOP> | <br>**Presenter / Lead author**<br><BORDER_TOP> | <br>**Presentation details**<br><BORDER_TOP> |
| **<br>SPONSORED STUDIES** | **<br>SPONSORED STUDIES** | **<br>SPONSORED STUDIES** |
| **Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)** | Zhenhua Liu<br>(Chengdu, China) | 2592MO<br>Mini Oral Session 1: <br>GU tumours, renal & urothelial<br>Friday, Oct 17, 2025<br>Karlsruhe Auditorium - Hall 5.2<br>16:00 - 17:30 CEST |
| **A Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC)** | Stefan Kasper-Virchow <br>(Essen, Germany) | 794P <br>Poster Session: <br>Colorectal cancer |
| **Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 study** | N. Arvind Dasari <br>(Houston, USA) | 799P<br>Poster Session: <br>Colorectal cancer |
| **A novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC)** | Sara Lonardi <br>(Padua, Italy) | 804P<br>Poster Session: <br>Colorectal cancer |
| **Safety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancer** | Cathy Eng <br>(Nashville, USA) | 811P<br>Poster Session: <br>Colorectal cancer |
| **Association between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 study** | Danbo Wang <br>(Shenyang, China) | 1230eP <br>Poster Session: <br>Gynaecological Cancer  |
| **ctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)** | Yongfeng Yu <br>(Shanghai, China) | 1954P <br>Poster Session: <br>NSCLC, metastatic |
| **SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi** | Quincy Siu-chung Chu <br>(Edmonton, Canada) | 1955P <br>Poster Session: <br>NSCLC, metastatic |
| **MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) study** | Julia Rotow <br>(Boston, USA) | 1956P <br>Poster Session: <br>NSCLC, metastatic |

---

------

---

| | | |
|:---|:---|:---|
| <br>**Abstract title**<br><BORDER_TOP> | <br>**Presenter / Lead author**<br><BORDER_TOP> | <br>**Presentation details**<br><BORDER_TOP> |
| <br>**INVESTIGATOR-INITIATED STUDIES** | <br>**INVESTIGATOR-INITIATED STUDIES** | <br>**INVESTIGATOR-INITIATED STUDIES** |
| **Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trial** | Fei Ma <br>(Zhengzhou, China) | 2159P <br>Poster Session: Oesophagogastric cancer |
| **Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II Study** | Wangjun Liao <br>(Guangzhou, China) | 898eP<br>E-poster Session:<br>Colorectal cancer |
| **The efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical study** | Qianqian Wang <br>(Nanjing, China) | 929P <br>Poster Session: <br>Developmental therapeutics |
| **Surufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination Regimens** | Yanfang Zheng<br>(Guangzhou, China) | 1884P<br>Poster Session:<br>NSCLC, metastatic |
| **Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase ll Results from a Single-Center Trial** | Wenfeng Fang/ Li Zhang<br>(Guangzhou, China) | 1887P<br>Poster Session: <br>NSCLC, metastatic |
| **Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancer** | Song Gao/ Jihui Hao<br>(Tianjin, China) | 2236P<br>Poster Session: <br>Pancreatic cancer |
| **Efficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II Study** | Xiaowei Zhang/ Zhiguo Luo<br>(Shanghai, China) | 2716P<br>Poster Session: <br>Sarcoma |

---

#### About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ("VEGFR") -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE<sup>®</sup>. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA<sup>®</sup>.

#### About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS<sup>®</sup>.

#### About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body's immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA<sup>®</sup>. HUTCHMED currently retains all rights to surufatinib worldwide.

#### About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch med.com or follow us on LinkedIn.

------

#### Forward-Looking Statements
*This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.*

#### Medical Information
*This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.* 

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / ir@hutch-med.com |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| &nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Alex Shaw | &nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| **Panmure Liberum** | *Nominated Advisor and Joint Broker* |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| **Cavendish** | *Joint Broker* |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | *Joint Broker* |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

------